Melflufen: A Next-Generation Nitrogen Mustard
- 1 March 2021
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (7), 836-839
- https://doi.org/10.1200/jco.20.03326
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma CellsClinical Cancer Research, 2013
- Aminopeptidase N (CD13) as a target for cancer chemotherapyCancer Science, 2011
- The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalanBiochemical Pharmacology, 2010
- The moonlighting enzyme CD13: old and new functions to targetTrends in Molecular Medicine, 2008
- The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitroInvestigational New Drugs, 2007
- Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalanAnti-Cancer Drugs, 2003
- Activity of Hydrolytic Enzymes in Tumour Cells is a Determinant for Anti-tumour Efficacy of the Melphalan Containing ProdrugJ1Journal of Drug Targeting, 2003
- Derivatives of Melphalan Designed to Enhance Drug Accumulation in Cancer CellsJournal of Drug Targeting, 1997
- Cellular pharmacokinetics of the phenylalanine mustardsPharmacology & Therapeutics, 1983
- The initial clinical trial of nitrogen mustardThe American Journal of Surgery, 1963